Denis Chem Lab: Daga Group Boosts Stake to 9.64% Amid Stock Pressure

The Varun Daga Family Trust, alongside Persons Acting in Concert (PACs) including Shreans Daga Family Trust and Kanchan Daga, has acquired 2,67,499 shares of Denis Chem Lab Limited. This off-market purchase, representing a 1.93% stake, was executed on March 27, 2026, and reported on March 30, 2026. Following this transaction, the collective holding of the Daga group in Denis Chem Lab now stands at 9.64% of the company's equity, out of a total paid-up equity share capital of ₹13.88 crore (1,38,76,668 shares).

This strategic increase in ownership by the Daga group signals heightened interest and potentially a consolidation of holdings by a key investor base. It arrives at a time when Denis Chem Lab's stock has been experiencing significant downward pressure, recently reaching new 52-week lows and trading in the ₹57-₹60 range.

Denis Chem Lab, established in 1980 and based in Ahmedabad, operates as a pharmaceutical company specializing in sterile intravenous injectable products for human and veterinary use, also offering contract manufacturing services. Despite a strong 88.6% year-on-year rise in net profit to ₹3.32 crore for the quarter ending December 2025, the company's annual performance for fiscal year 2025 saw a decline. It maintains a very low debt-to-equity ratio.

However, the company faces several challenges. Historically, sales growth has been noted as weak by some observers. Furthermore, past regulatory scrutiny, including a drug supply case in Madhya Pradesh in 2020, remains a historical concern for the company.

In the broader pharmaceutical sector, Denis Chem Lab is a micro-cap player compared to giants like Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Cipla Ltd., and Dr Reddy's Laboratories Ltd. Its 1-year return of -37.33% significantly underperforms its peers, and its growth metrics are generally considered below average.

Investors will be monitoring potential future strategic moves by the Daga group, alongside Denis Chem Lab's ability to show sustained improvement in profitability and revenue growth. Tracking the stock's performance against market trends and its peer group will also be key.